MA56783B1 - Procédé de préparation d'ivosidenib et d'un intermédiaire de celui-ci - Google Patents
Procédé de préparation d'ivosidenib et d'un intermédiaire de celui-ciInfo
- Publication number
- MA56783B1 MA56783B1 MA56783A MA56783A MA56783B1 MA 56783 B1 MA56783 B1 MA 56783B1 MA 56783 A MA56783 A MA 56783A MA 56783 A MA56783 A MA 56783A MA 56783 B1 MA56783 B1 MA 56783B1
- Authority
- MA
- Morocco
- Prior art keywords
- ivosidenib
- preparing
- synthesis
- preparation
- relates
- Prior art date
Links
- WIJZXSAJMHAVGX-DHLKQENFSA-N ivosidenib Chemical compound FC1=CN=CC(N([C@H](C(=O)NC2CC(F)(F)C2)C=2C(=CC=CC=2)Cl)C(=O)[C@H]2N(C(=O)CC2)C=2N=CC=C(C=2)C#N)=C1 WIJZXSAJMHAVGX-DHLKQENFSA-N 0.000 title abstract 2
- 229950010738 ivosidenib Drugs 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
La présente invention concerne un procédé de préparation d'un solvate éthanol cristallin sensiblement pur et diastéréomériquement pur du composé iia et son utilisation pour la synthétisation de l'ivosidenib.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962884480P | 2019-08-08 | 2019-08-08 | |
| PCT/US2020/045368 WO2021026436A1 (fr) | 2019-08-08 | 2020-08-07 | Procédé de préparation d'ivosidenib et d'un intermédiaire de celui-ci |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA56783B1 true MA56783B1 (fr) | 2023-10-31 |
Family
ID=74504162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA56783A MA56783B1 (fr) | 2019-08-08 | 2020-08-07 | Procédé de préparation d'ivosidenib et d'un intermédiaire de celui-ci |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US12479824B2 (fr) |
| EP (1) | EP4010331B1 (fr) |
| JP (1) | JP7644747B2 (fr) |
| KR (1) | KR20220061971A (fr) |
| CN (1) | CN114555584B (fr) |
| AU (1) | AU2020327013B2 (fr) |
| BR (1) | BR112022002253A2 (fr) |
| CA (1) | CA3150028A1 (fr) |
| CL (1) | CL2022000310A1 (fr) |
| CO (1) | CO2022001991A2 (fr) |
| CR (1) | CR20220090A (fr) |
| DK (1) | DK4010331T3 (fr) |
| EC (1) | ECSP22016924A (fr) |
| ES (1) | ES2967909T3 (fr) |
| FI (1) | FI4010331T3 (fr) |
| GE (2) | GEAP202415882A (fr) |
| HR (1) | HRP20231618T1 (fr) |
| HU (1) | HUE064193T2 (fr) |
| IL (1) | IL290377B2 (fr) |
| LT (1) | LT4010331T (fr) |
| MA (1) | MA56783B1 (fr) |
| MD (1) | MD4010331T2 (fr) |
| MX (1) | MX2022001619A (fr) |
| MY (1) | MY207344A (fr) |
| PE (1) | PE20221761A1 (fr) |
| PH (1) | PH12022550266A1 (fr) |
| PL (1) | PL4010331T3 (fr) |
| PT (1) | PT4010331T (fr) |
| RS (1) | RS64934B1 (fr) |
| SI (1) | SI4010331T1 (fr) |
| SM (1) | SMT202300489T1 (fr) |
| TW (1) | TWI890687B (fr) |
| WO (1) | WO2021026436A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR133410A1 (es) | 2023-08-01 | 2025-09-24 | Servier Lab | Cocristal de un inhibidor de idh1, proceso de preparación del mismo, composiciones farmacéuticas del mismo, y métodos de tratamiento que implican el mismo |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006067445A2 (fr) | 2004-12-22 | 2006-06-29 | Astrazeneca Ab | Composes chimiques |
| US7910595B2 (en) | 2005-12-21 | 2011-03-22 | Abbott Laboratories | Anti-viral compounds |
| US9474779B2 (en) * | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
| NZ723859A (en) | 2014-03-14 | 2023-01-27 | Servier Lab | Pharmaceutical compositions of therapeutically active compounds and their uses |
| BR112017006425B8 (pt) | 2014-10-01 | 2023-05-16 | Daiichi Sankyo Co Ltd | Compostos derivados de isoxazol, seus usos, inibidores de isocitrato desidrogenase 1 mutante e da produção de d-2 hidroxiglutamato, agente antitumoral e composição farmacêutica compreendendo os mesmos |
| US11066390B2 (en) * | 2017-11-27 | 2021-07-20 | Assia Chemical Industries Ltd. | Solid state forms of Ivosidenib |
| EA202190217A1 (ru) | 2018-07-06 | 2021-04-16 | Аджиос Фармасьютикалз, Инк. | Формы ивосидениба и фармацевтические композиции |
| WO2020127887A1 (fr) | 2018-12-21 | 2020-06-25 | Sandoz Ag | Procédé de préparation d'un produit intermédiaire d'ivosidénib |
-
2020
- 2020-08-07 AU AU2020327013A patent/AU2020327013B2/en active Active
- 2020-08-07 WO PCT/US2020/045368 patent/WO2021026436A1/fr not_active Ceased
- 2020-08-07 PH PH1/2022/550266A patent/PH12022550266A1/en unknown
- 2020-08-07 RS RS20231183A patent/RS64934B1/sr unknown
- 2020-08-07 KR KR1020227007851A patent/KR20220061971A/ko active Pending
- 2020-08-07 US US17/634,524 patent/US12479824B2/en active Active
- 2020-08-07 EP EP20758409.5A patent/EP4010331B1/fr active Active
- 2020-08-07 ES ES20758409T patent/ES2967909T3/es active Active
- 2020-08-07 GE GEAP202415882A patent/GEAP202415882A/en unknown
- 2020-08-07 MY MYPI2022000677A patent/MY207344A/en unknown
- 2020-08-07 PE PE2022000203A patent/PE20221761A1/es unknown
- 2020-08-07 GE GEAP202015882A patent/GEP20247709B/en unknown
- 2020-08-07 PL PL20758409.5T patent/PL4010331T3/pl unknown
- 2020-08-07 IL IL290377A patent/IL290377B2/en unknown
- 2020-08-07 PT PT207584095T patent/PT4010331T/pt unknown
- 2020-08-07 SM SM20230489T patent/SMT202300489T1/it unknown
- 2020-08-07 HR HRP20231618TT patent/HRP20231618T1/hr unknown
- 2020-08-07 HU HUE20758409A patent/HUE064193T2/hu unknown
- 2020-08-07 LT LTEPPCT/US2020/045368T patent/LT4010331T/lt unknown
- 2020-08-07 CA CA3150028A patent/CA3150028A1/fr active Pending
- 2020-08-07 MA MA56783A patent/MA56783B1/fr unknown
- 2020-08-07 SI SI202030329T patent/SI4010331T1/sl unknown
- 2020-08-07 FI FIEP20758409.5T patent/FI4010331T3/fi active
- 2020-08-07 JP JP2022507572A patent/JP7644747B2/ja active Active
- 2020-08-07 DK DK20758409.5T patent/DK4010331T3/da active
- 2020-08-07 BR BR112022002253A patent/BR112022002253A2/pt unknown
- 2020-08-07 MX MX2022001619A patent/MX2022001619A/es unknown
- 2020-08-07 CN CN202080070672.3A patent/CN114555584B/zh active Active
- 2020-08-07 TW TW109126862A patent/TWI890687B/zh active
- 2020-08-07 CR CR20220090A patent/CR20220090A/es unknown
- 2020-08-07 MD MDE20220658T patent/MD4010331T2/ro unknown
-
2022
- 2022-02-07 CL CL2022000310A patent/CL2022000310A1/es unknown
- 2022-02-24 CO CONC2022/0001991A patent/CO2022001991A2/es unknown
- 2022-03-07 EC ECSENADI202216924A patent/ECSP22016924A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR3087439B1 (fr) | Procédé pour la préparation de 3α-hydroxy-5α-prégnan-20-one (brexanolone) | |
| AR043940A1 (es) | Inhibidores de sulfonamidas heterociclicas que contienen fluor- y trifluoralquilo de la produccion de beta amiloides y derivados de los mismos | |
| MA56508B1 (fr) | Inhibiteur de l'egfr pour le traitement du cancer | |
| MX2021000348A (es) | 2-fluoro-3-nitrotolueno cristalino y procedimiento para la preparacion del mismo. | |
| ZA202201503B (en) | Urea compound for antagonizing lpa1 receptor | |
| CO6290666A2 (es) | Antagonistas del receptor de nmda para neuroproteccion | |
| MX2022005403A (es) | Forma cristalina de base libre de un receptor del componente c5a de complemento. | |
| MA40895A (fr) | Synthèse de copanlisib et son sel de dichlorhydrate | |
| MX2021007258A (es) | Composiciones de esparsentan amorfas. | |
| MA56783B1 (fr) | Procédé de préparation d'ivosidenib et d'un intermédiaire de celui-ci | |
| NO20054669L (no) | Substituerte kinobenzoxazinanaloger | |
| CA3242297A1 (fr) | Procede de preparation de derives de benzimidazole | |
| MX2020002436A (es) | Antagonistas del receptor de vasopresina y productos y metodos relacionados a los mismos. | |
| MX2023004102A (es) | Derivado de gamma-carbolina fusionado sustituido con heterociclo, metodo de preparacion del mismo, intermediarios del mismo y uso del mismo. | |
| MX2023007429A (es) | Uso como agonista selectivo de receptor de melanocortina-4. | |
| SA520412408B1 (ar) | عملية تحضير مركبات ثنائي أريل أوكسي بنزو ديازول غير متجانسة مزدوجة الاستبدال | |
| MA58104B1 (fr) | Procédé et intermédiaire pour la préparation d'oxétane-2-ylméthanamine | |
| MX2024005066A (es) | Compuestos de cd73. | |
| MX2025000464A (es) | Forma cristalina de un esteroide neuroactivo | |
| PH12021551794A1 (en) | Polymorphic forms of a substituted-quinoxaline-type bridged-piperidine compound | |
| PH12021550248A1 (en) | Borate of azetidine derivative | |
| MX2023010044A (es) | Compuesto para el tratamiento de trastornos cognitivos. | |
| MX2023011482A (es) | Proceso para preparar compuestos de cetona biciclicos. | |
| ECSP034489A (es) | Farmacos para ligandos del receptor nmda | |
| AR115012A1 (es) | Derivados de aminopropoxifenilo y bencil 1-oxa-4,9-diazaespiroundecano con actividad multimodal contra el dolor |